Last reviewed: June 19, 2026
Last updated: June 19, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide (Wegovy) and tirzepatide (Mounjaro) are both GLP-1 receptor agonists that work on appetite and metabolism, but tirzepatide adds a second mechanism by also targeting the GIP receptor. Clinical trials show tirzepatide produces approximately 20% body weight reduction compared to semaglutide's 15-17% at equivalent dose levels.
How Semaglutide and Tirzepatide Work Differently
Semaglutide activates only the GLP-1 receptor, which signals fullness to your brain and slows stomach emptying. This single-action approach has been proven in multiple large trials and forms the foundation of Wegovy's FDA authorization. Semaglutide also improves blood sugar control and may support cardiovascular health in people with diabetes.
Tirzepatide acts on both GLP-1 and GIP receptors simultaneously, creating what researchers call a dual-agonist effect. This dual mechanism appears to enhance weight loss beyond what semaglutide alone achieves by addressing appetite suppression through two distinct neural pathways. The combination also influences how your body processes glucose and may improve metabolic flexibility.
Clinical Evidence: Weight Loss Outcomes You Should Know
The STEP trials demonstrated that semaglutide achieves approximately 15-17% average body weight loss over 68 weeks in people without diabetes. Participants typically experience steady, progressive weight loss, with most benefit appearing between weeks 12 and 32 of treatment. Response varies based on genetics, adherence, lifestyle factors, and baseline metabolic health.
The SURMOUNT trials showed tirzepatide produces mean weight loss of 20-22% over 72 weeks, with some participants reaching 25% or greater reduction. This greater efficacy may result from the dual GLP-1/GIP mechanism engaging more pathways simultaneously. Individual outcomes depend on genetic factors affecting GLP1R and GIPR signaling, which PlexusDx can evaluate through the Precision Peptide Genetic Test.
Understanding the Cost Difference Between Your Options
Brand-name Wegovy typically costs $900-$1,300 per month depending on dose, while brand Mounjaro ranges from $1,000-$1,350 monthly. Many patients lack insurance coverage for weight loss, making these prices prohibitive. PlexusDx offers compounded semaglutide starting at $149 per month and compounded tirzepatide injection starting at $249 per month—all from licensed 503A compounding pharmacies.
PlexusDx's pricing structure guarantees your monthly cost stays flat as your dose increases, so you never pay more as your treatment advances. Both medications are HSA and FSA eligible through PlexusDx, and no insurance or membership is required. Patients can also access the GLP-Squared dual-compound option starting at $249 monthly, combining semaglutide and tirzepatide in one injection for those seeking maximum versatility.
Choosing Between Them: Personalization and Genetic Factors
Response to GLP-1 medications varies dramatically between individuals due to genetic differences in GLP1R and GIPR expression. Some people show excellent results on semaglutide alone, while others benefit from tirzepatide's dual-action approach. PlexusDx uses the Precision Peptide Genetic Test to analyze 14 metabolic pathways and 150+ genetic insights, including variants in GLP1R (rs6923761) and GIPR (rs1800437) that influence treatment response.
The Precision Peptide test, available as a $99 add-on after your first month of treatment, helps predict which therapy aligns best with your biological makeup. Patients with genetic profiles showing stronger GLP1R response may achieve equal results on semaglutide, while those with variations affecting GIP signaling often show superior outcomes on tirzepatide. This personalized approach eliminates guesswork and maximizes your likelihood of success.
Side Effects: What to Expect and How They Compare
Both medications share common GLP-1 side effects including nausea, vomiting, constipation, and abdominal pain, particularly during dose escalation. Semaglutide side effects typically diminish within days to weeks as your body adapts. Severe adverse events are rare, but pancreatitis, gallbladder complications, and thyroid concerns require medical monitoring in both therapies.
Tirzepatide may cause slightly higher rates of gastrointestinal symptoms due to its dual mechanism, though most patients tolerate it well. Starting with a low dose and gradually increasing—a strategy PlexusDx supports with flexible dosing options—significantly reduces nausea and vomiting. Your treatment plan should include regular check-ins to assess tolerability and adjust your dose if side effects become problematic.
Injectable vs. Oral: Delivery Options for Your Lifestyle
PlexusDx offers both semaglutide and tirzepatide in injectable and oral forms. Compounded semaglutide injection begins at $149 monthly, while oral semaglutide starts at $249 monthly. Tirzepatide injection costs $249 monthly and oral tirzepatide runs $279 monthly, providing flexibility based on your comfort with needles and medication absorption.
Oral medications offer convenience and privacy but require an empty stomach and careful timing away from other substances. Injectable forms deliver medication directly into subcutaneous tissue, bypassing digestive absorption variables and ensuring consistent dosing. Many patients prefer injectables for their reliability and once-weekly dosing schedules, while others value the simplicity of daily oral tablets.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is tirzepatide actually more effective than semaglutide for weight loss?
Clinical trials show tirzepatide produces approximately 5% greater average weight loss than semaglutide—roughly 20% versus 15% body weight reduction. However, individual response varies significantly based on genetics, adherence, and lifestyle. PlexusDx's Precision Peptide Genetic Test identifies your genetic predisposition to GLP-1 and GIP signaling, helping predict which medication may work best for your specific biology.
Can I switch from Wegovy to Mounjaro if I'm not seeing results?
Yes, patients who plateau on semaglutide often see renewed weight loss after transitioning to tirzepatide. The switch typically requires a washout period and dose adjustment. PlexusDx supports medication transitions and can provide both semaglutide and tirzepatide options, allowing your provider to pivot your therapy based on your individual response patterns.
How much will I save using PlexusDx compounded medications?
PlexusDx compounded tirzepatide injection starts at $249 monthly compared to $1,000+ for brand Mounjaro—a savings of 75% or more. Semaglutide from PlexusDx begins at $149 monthly versus $900+ for brand Wegovy. These prices remain flat regardless of dose increases, and both are HSA/FSA eligible with no insurance or membership required.
Are compounded semaglutide and tirzepatide as safe as brand-name versions?
PlexusDx sources all compounded medications from licensed 503A compounding pharmacies, which must meet strict FDA standards for quality, sterility, and potency. While compounded medications are not FDA-approved, they undergo rigorous pharmaceutical oversight. The active pharmaceutical ingredients are identical to brand versions; the primary difference is cost and accessibility.
What does the Precision Peptide Genetic Test tell me about my weight loss potential?
The Precision Peptide test analyzes 14 metabolic pathways and 150+ genetic insights, including key variants in GLP1R, GIPR, FTO, and MC4R genes. These variants influence appetite regulation, energy expenditure, and medication response. Understanding your genetic profile helps PlexusDx providers predict which medication—semaglutide, tirzepatide, or the dual GLP-Squared option—aligns with your biology for optimal results.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Why Ozempic Doesn’t Always Lead to Weight Loss for Everyone
How Soon After Starting Ozempic Do Side Effects Start?